Beta-1,3-glucuronyltransferase 3 (B3GAT3)

Beta-1,3-glucuronyltransferase 3 (B3GAT3) is a protein-coding enzyme that catalyzes the final step in the biosynthesis of the proteoglycan linkage region, specifically the transfer of a glucuronic acid residue from UDP-glucuronic acid to a core galactosylgalactosylxylosyl-protein trisaccharide structure at a serine residue. This enzyme is critical for the formation of glycosaminoglycan chains in proteoglycans, essential for normal connective tissue and extracellular matrix composition. B3GAT3 shows strict acceptor specificity and is linked to several developmental disorders when mutated, including specific types of congenital disorders of glycosylation and joint dysplasia syndromes. The protein is classified within the glucuronyltransferase gene family and plays a role in heparan/chondroitin sulfate biosynthesis and influences cell surface glycosylation patterns, including the HNK-1 epitope on glycoproteins.

Other names

Galactosylgalactosylxylosylprotein 3-beta-glucuronosyltransferase 3GlcAT-IGlcUAT-IGlucuronosyltransferase IUDP-GlcUA:Gal beta-1,3-Gal-R glucuronyltransferaseGLCATIJDSCDSqv-8-like protein

No approved drugs are known to target B3GAT3 directly; theoretical mechanisms could include: Enzyme inhibition (small molecule inhibitors to attenuate function in glycosylation disorders); Gene therapy/restoration (address genetic deficiency). These are speculative and not documented for approved therapies.